Full Breakdown
The Global Divide in Access to Keytruda: A Lifesaving Drug
4/13/2026, 1:18:12 PM
Overview of Keytruda's Impact
A yearlong investigation by Deutsche Welle (DW) and the International Consortium of Investigative Journalists (ICIJ) has revealed significant disparities in access to Keytruda (pembrolizumab), a cancer immunotherapy drug developed by Merck. While Keytruda has transformed cancer treatment and generated substantial revenue—$31.7 billion in sales in 2025 alone—its high cost and patent protections have created barriers for many patients worldwide.
Pricing and Access Challenges
Keytruda's annual treatment costs vary significantly across countries, ranging from approximately $65,000 in South Africa to $208,000 in the United States. These prices strain healthcare systems, even in affluent nations. For instance, the UK's National Health Service has been criticized for overpaying for Keytruda, with some patients facing costs up to five times higher than its assessed value. In lower-income countries like India and Brazil, access is often limited to those who can afford out-of-pocket payments or navigate complex legal systems to secure treatment.
Patent Strategies and Market Exclusivity
Merck has utilized an extensive patent strategy, filing over 1,212 applications across 53 jurisdictions. While the main patents for Keytruda are set to expire in 2028, follow-on patents could extend market exclusivity until at least 2042. Critics argue this creates a "patent fortress," hindering competition and delaying the introduction of more affordable alternatives. Merck counters that its patent filings reflect ongoing innovation and improvements in treatment.
The Role of Legal Systems
In countries like Turkey, where Keytruda's pricing is based on a government-set euro exchange rate, patients have resorted to litigation to access the drug. Despite entering the reimbursement system in July 2025 for certain indications, many patients still face eligibility restrictions. The investigation found that delays in legal proceedings often result in patients dying before receiving treatment, highlighting systemic issues in accessing life-saving medications.
Official Responses and Criticism
Merck has defended its pricing strategy, asserting that Keytruda's costs reflect its value to patients and healthcare systems. The company emphasizes that access to medicines is influenced by various factors, including healthcare infrastructure and reimbursement policies. However, critics, including public health advocates, argue that the current system exacerbates global inequalities in healthcare access.
Conflicting Reports on Development Costs
Merck CEO Robert M. Davis stated that the company invested $46 billion in Keytruda's development from 2011 to 2023. However, a report by the Swiss nonprofit Public Eye estimates the drug's research and development costs at around $1.9 billion, raising questions about the justification for its high pricing.
Conclusion: A Call for Equity in Healthcare
The investigation underscores a critical question posed by public health advocates: Should medical innovation be viewed as a common good for humanity or a commercial asset that deepens global inequality? The findings reveal a stark reality where access to life-extending treatments like Keytruda is often determined by geography, income, and the ability to navigate complex healthcare systems, leaving many patients without the care they need.
